Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Bent Mogensen"'
Autor:
Steen Olsen, Bent Mogensen
Publikováno v:
Acta Pathologica Microbiologica Scandinavica Section A Pathology. :453-456
Cellular reaction to primary and metastatic gestational choriocarcinoma (CHC) was observed in histological sections from all but one of the 23 patients included in this series. The reaction was slight in 8, moderate in 5, and marked in 9. The infiltr
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 82:2308-2313
Insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) recently have been shown to play a physiological role in the female genital system, including the ovarian follicular system. However, little is known about the role of the IGF syste
Publikováno v:
Kierkegaard, O, Mogensen, O, Mogensen, B & Jakobsen, A 1995, ' Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer ', Gynecologic Oncology, vol. 59, no. 2, pp. 251-4 . https://doi.org/10.1006/gyno.1995.0017
CA 125 and cancer-associated serum antigen (CASA) were measured prior to second-look laparotomy (SLL) to investigate their predictive and prognostic values in 93 patients treated for epithelial ovarian cancer FIGO stage II, III, or IV. Residual tumor
Publikováno v:
British Journal of Cancer
Mogensen, O, Mogensen, B & Jakobsen, A 1990, ' Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours ', British Journal of Cancer, vol. 61, no. 2, pp. 327-9 . https://doi.org/10.1038/bjc.1990.64
Mogensen, O, Mogensen, B & Jakobsen, A 1990, ' Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours ', British Journal of Cancer, vol. 61, no. 2, pp. 327-9 . https://doi.org/10.1038/bjc.1990.64
A tumour-associated trypsin inhibitor (TATI) and the cancer antigen 125 (CA 125) were measured pre- or peroperatively in 30 patients with mucinous ovarian tumours (10 malignant, two borderline and 18 benign) to investigate the separate and combined u
Autor:
Bent Nørgaard-Pedersen, Inge Clemmensen, Severin Olesen Larsen, Claus Høgdall, Anders Jakobsen, Bent Mogensen, Ann Tabor, Ole Mogensen
Publikováno v:
Høgdall, C K, Mogensen, O, Tabor, A, Mogensen, B, Jakobsen, A K, Nørgaard-Pedersen, B, Larsen, S O & Clemmensen, I 1995, ' The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors ', Gynecologic Oncology, vol. 56, no. 1, pp. 22-8 . https://doi.org/10.1006/gyno.1995.1004
Serum tetranectin (Se-TN) and CA-125 were measured in 315 patients with a pelvic tumor and 458 healthy females. At a false-positive rate of 0.7% the sensitivity for ovarian cancer stage 1 and 2 was 33% for Se-TN and 76% for both CA 125 and an index b
Publikováno v:
Mogensen, O, Mogensen, B & Jakobsen, A 1990, ' Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses ', Gynecologic Oncology, vol. 38, no. 2, pp. 170-4 . https://doi.org/10.1016/0090-8258(90)90035-j
Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA-125) were measured pre- and peroperatively in 183 patients with a pelvic mass to elucidate the value of TATI alone and in combination with CA-125 as a differential diagnostic tool.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b734802dcafd97dab3c1c256067ab06
https://pure.au.dk/portal/da/publications/tumorassociated-trypsin-inhibitor-and-cancer-antigen-125-in-pelvic-masses(bb2fe772-fade-4a73-a2ce-e7978136e489).html
https://pure.au.dk/portal/da/publications/tumorassociated-trypsin-inhibitor-and-cancer-antigen-125-in-pelvic-masses(bb2fe772-fade-4a73-a2ce-e7978136e489).html
Publikováno v:
Mogensen, O, Mogensen, B & Jakobsen, A 1990, ' Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer ', Gynecologic Oncology, vol. 37, no. 1, pp. 44-6 . https://doi.org/10.1016/0090-8258(90)90305-5
CA 125 was measured during early chemotherapy of 61 patients with epithelial ovarian carcinomas (PIG0 stages III and IV) to determine if patients with a poor response to further treatment could be identified during early therapy. Blood samples were d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d068407ae2f24650ac8d0e29e6ad3e1
https://pure.au.dk/portal/da/publications/predictive-value-of-ca-125-during-early-chemotherapy-of-advanced-ovarian-cancer(3e160871-e02b-4c65-b40c-568067c88320).html
https://pure.au.dk/portal/da/publications/predictive-value-of-ca-125-during-early-chemotherapy-of-advanced-ovarian-cancer(3e160871-e02b-4c65-b40c-568067c88320).html
Publikováno v:
Cancer. 33:1458-1461
Autor:
Bent Mogensen, Steen Olsen
Publikováno v:
Acta Obstetricia et Gynecologica Scandinavica. 51:63-69
In Denmark, 94 cases of trophoblastic disease were classified as choriocarcinoma (CHC) or “probably CHC” during the period 1940–1969. All these cases were subjected to a reappraisal in the study presented here. Based on the criteria laid down b
Autor:
F. Kissmeyer-Nielsen, Bent Mogensen
Publikováno v:
Obstetrical & Gynecological Survey. 23:952-960